Drug Profile


Alternative Names: CD24-Fc; CD24-Fc-IgG; CD24Fc-fusion protein; HAS-CD24; Recombinant CD24 IgG1 Fc fusion protein; Recombinant human CD24FcIg

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoImmune
  • Developer National Institute of Neurological Disorders and Stroke; Ohio State University; OncoImmune; University of Michigan Comprehensive Cancer Center
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Graft-versus-host disease
  • No development reported Autoimmune disorders

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in USA (IV)
  • 01 Aug 2016 Phase-II clinical trials in Graft-versus-host disease (Prevention) in USA (IV) (NCT02663622)
  • 21 Jan 2016 University of Michigan Cancer Center and Ohio State University plans a phase II trial for Graft-versus-host disease (Prevention) in USA (NCT02663622)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top